All Articles

As rural hospitals face financial collapse, a new wave of AI-powered technology is proving it can stabilize finances and preserve access to essential care.

TelyRx just filled its millionth prescription, but the real story isn't the number. It's the 'operational innovation' of its cash-pay model that's disrupting healthcare.

BestFarewell's appointment of Rianka Dorsainvil isn't just a hire; it's a signal. A look at how AI and human expertise are converging in a new system for legacy.

Promising early data for obesity drug DA-1726 shows rapid weight loss, while vanoglipel demonstrates powerful synergy in MASH and diabetes combination therapies.

TOYO's landmark investment in a Houston HJT solar cell facility signals a new era for America's energy independence and high-efficiency manufacturing.

Patagonia Gold celebrates first gold from its Calcatreu mine, a major operational win that ignites Argentina's Rio Negro economy amid deep-seated local dissent.

Beta Bionics faces a shareholder investigation after a slowdown in patient growth spooked investors. We decode the numbers and the broader risks of growth metrics.

As the world's biggest sporting event expands across North America, a new digital guide aims to be a crucial safety net. Is this the new playbook for mega-events?

With healthcare drowning in a $1 trillion administrative burden, CAQH's rebrand to DataSpring is more than a name change—it's a high-stakes bet.

With its new CryoTherm Palm, Therabody bets on thermoregulation to boost athletic power. We analyze the science, the strategy, and what it means for the future of wellness tech.

Hub International appoints Faizal Mitha as VP of AI Sales Innovation, a move to embed AI in sales and drive growth, setting a new bar for the industry.

A key hospitality tech acquisition signals a major shift from fixing Wi-Fi problems to proactively validating the entire network, a move with broad implications.

Kymera Therapeutics' new lupus data isn't just about a drug. It's about a new strategy: erasing disease-causing proteins to build resilient value.

VENU's $50M sale-leaseback fuels a rapid expansion. But is its innovative financial model a new blueprint for growth or a high-stakes bet on the future?

Calpine's new 25MW geothermal expansion at The Geysers provides baseload power for 25,000 homes, boosting California's grid and cementing Constellation's strategy.

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

A novel partnership aims to power a Newfoundland nickel mine with hydrogen generated from the mine's own rock, a first-of-its-kind model for green industry.

Beyond a simple plea for donations, Héma-Québec is executing a sophisticated strategic campaign to secure Quebec's most vital, and volatile, supply chain.

Mineralys Therapeutics' Lorundrostat shows promise in reducing heart failure risk, a breakthrough for millions struggling with uncontrolled hypertension.